about
Addition of pamidronate to chemotherapy for the treatment of osteosarcomaDickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathwayMethotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good RQuantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrierPhase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyOutcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.Ewing's sarcoma/primitive neuroectodermal tumor of the ureter: a case report and review of the literature.A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.Osteosarcoma treatment - where do we stand? A state of the art review.A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults.Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: an institutional review.Ewing's sarcoma.Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatmentBody mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology GroupBiology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology GroupRecurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review.Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature.Ewing's sarcoma and primitive neuroectodermal family of tumors.Prognostic factors and survival in pediatric and adolescent liposarcomaTreatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma.Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of OsteosarcomaIntensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.Quality of life following amputation or limb preservation in patients with lower extremity bone sarcomaIdentification of Discrete Prognostic Groups in Ewing SarcomaRadiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.Positron emission tomography for response assessment in desmoplastic small round cell tumor.Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
P50
Q24594269-7D5F4B13-F2B8-42F2-AF25-2F10422BB620Q28256833-D127847D-C808-4380-8B2E-BBDD9B53BFC5Q30357731-95552B78-34EA-4E18-8BCE-8DBADBE23910Q33331479-331D8FEB-EE50-4B65-BA7F-37430FDCA372Q33349428-2448CC57-3E91-4974-A011-4CD2ADA448BFQ33385564-C52F9043-DF09-4211-B56A-2E351A2F051CQ33397796-FB186D94-51B4-41E2-AB98-241904520D5BQ33559539-B051657E-5FD7-4C84-A4AB-745D347F4730Q34023544-5EF1B0C7-6279-434E-97CD-ADA67A0CA8C7Q34041542-591F0D7C-6936-40EC-AD8E-1A10AE72D1D4Q34369388-42DD3F3C-3CB1-4FCD-AEBB-AE9EB79B1A8CQ34392457-A3F35B60-C7C9-4C04-A7D5-06B1099C23D3Q34507108-4FBAA563-7FEA-49D3-8697-337BA544F673Q34564164-CE62B0F2-39A7-484A-9213-60DDD429D066Q34650422-139DAF31-2655-4891-B3DC-7C9918015380Q34678834-F93409E2-F0F2-412E-B462-3F1B23879C4FQ34743615-FC681E8E-59F8-4991-961E-B9EB5C6AFFD1Q34887225-EBDAA1A8-C788-4F6E-A8D9-BC4A486AD2EFQ34996698-13016C24-4BF3-4706-AE15-8EF2ED91730EQ35005741-279163DE-A854-4ECF-9366-35D4DE6D2D79Q35103631-1ADE3235-4523-4FA9-9982-2F98BFF64964Q35599920-910A3A6F-75F0-4135-9464-CAD223FD658DQ35615792-2A7869CF-4E0E-46AE-874E-DDE6B8BB13F4Q35677274-48352C81-3DF0-46B0-A2CB-0C33487C20F7Q36056793-8DC417E5-1538-4AB3-8345-670A9C2DEE63Q36153561-10B655CD-72B7-4B79-83AB-5723FBF671F9Q36237624-4205D3AE-AD2B-44FD-86C4-33DCB7901276Q36277346-C759397C-C29E-41C4-BA41-55DBAE015CA7Q36367217-B6A30ADF-825D-4079-A361-2F4602FC9978Q36389203-F7FAF9CC-5BB0-4498-B1A5-F27E0D1975D7Q36391637-2E24D8D3-3683-4980-A367-4FDB3413AE47Q36653789-8B8BC7FB-AF57-4457-AD82-B54FD711AECDQ37081539-5E7728B1-D9D6-4820-BB6D-861663C7D0B5Q37094141-9C314A15-FB26-44D8-8F2A-F588B8104A42Q37232948-2F67FA23-795D-44C3-BA40-54C715413771Q37301399-9D9AE5BF-C13D-48B2-B6FD-32792C361070Q37439345-DF029321-8512-444B-9423-CD075F9D164CQ37807268-E19C93C5-1278-4B3E-BA63-B919FBA21FE2Q38052731-CCE804E1-D8D4-400D-A8A2-0EAD5D4B7C44Q38198713-53C83656-3F38-448A-8A4F-F734838BFAEF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paul Meyers
@ast
Paul Meyers
@en
Paul Meyers
@es
Paul Meyers
@nl
Paul Meyers
@sl
type
label
Paul Meyers
@ast
Paul Meyers
@en
Paul Meyers
@es
Paul Meyers
@nl
Paul Meyers
@sl
prefLabel
Paul Meyers
@ast
Paul Meyers
@en
Paul Meyers
@es
Paul Meyers
@nl
Paul Meyers
@sl
P106
P1153
7102316384
P21
P31
P496
0000-0001-6146-6101